ResearchingRefreshing GILD from the latest filings.
1 of 8 sections ready
As of Sep 6, 2026, 2:26 PM
Price Chart
Overview
Gilead Sciences develops and sells medicines for HIV, liver diseases, cancer, COVID-19 and other serious illnesses, earning most of its revenue from a large portfolio of marketed drugs rather than from licensing. Its most important product is Biktarvy, a once-daily HIV treatment that generated $3.8 billion in sales in the three months ended June 30, 2026, while the company’s newest major HIV product, Yeztugo, is a twice-yearly HIV-prevention medicine already launched in the United States in 2025. Gilead’s technology base combines antiviral small-molecule drugs, antibody-drug conjugates such as Trodelvy, and CAR-T cell therapies, with current growth efforts focused on expanding HIV prevention, oncology and liver-disease products rather than relying on a single development-stage program.
The opportunity is a cash-generating HIV franchise: product sales were $7.6 billion in the three months ended June 30, 2026, HIV sales were $5.7 billion in that period, Biktarvy sales were $3.8 billion, and total revenue was $14.8 billion for the six months ended June 30, 2026; management also reported 2025 full-year product sales of $28.9 billion and 2026 full-year product-sales guidance of $30.0–$30.4 billion. The key risk is pipeline and acquisition execution: Gilead reported a $10.5 billion net loss for the three months ended June 30, 2026, driven largely by $11.2 billion of acquired in-process research-and-development expense and a $1.75 billion impairment charge in that quarter, while oncology and cell-therapy products face competition and the company’s valuation cannot be assessed here because no current share price or market-cap figure was sourced in the permitted search.